A5022420944- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Viral-associated cancers and disorders
- Genetic factors in colorectal cancer
- Multiple Myeloma Research and Treatments
- Molecular Biology Techniques and Applications
- Glycosylation and Glycoproteins Research
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- SARS-CoV-2 and COVID-19 Research
- Genomics and Rare Diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Lung Cancer Diagnosis and Treatment
- Hematological disorders and diagnostics
- Immune Cell Function and Interaction
- PI3K/AKT/mTOR signaling in cancer
- COVID-19 Clinical Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Thyroid Cancer Diagnosis and Treatment
Jessa Hospital
2016-2025
Hasselt University
2018-2025
Rega Institute for Medical Research
2024
KU Leuven
1999-2024
Delta State University
2021
Deutschen Konsortium für Translationale Krebsforschung
2020
Los Alamos National Laboratory
2012
Hartcentrum Hasselt
2009
PAMM
2002
Kiel University
2002
The European Myeloma Network has organized two workshops on fluorescence in situ hybridization multiple myeloma. first aimed to identify specific indications and consensus technical approaches of current practice. A second workshop followed a quality control exercise which 21 laboratories analyzed diagnostic cases purified plasma cells for recurrent abnormalities. summary report was discussed at the EHA Scientific Working Group Meeting 2010. During exercise, there acceptable agreement more...
Abstract Antibodies targeting the immune checkpoint molecules PD-1, PD-L1 and CTLA-4, administered alone or in combination with chemotherapy, are standard of care most patients metastatic non-small-cell lung cancers. When given before curative surgery, tumor responses improved event-free survival achieved. New antibody combinations may be more efficacious tolerable. In an ongoing, open-label phase 2 study, 60 biomarker-unselected, treatment-naive resectable cancer were randomized to receive...
Abstract ALK‐positive anaplastic large‐cell lymphoma (ALCL) has been recognized as a distinct type of in the heterogeneous group T/Null‐ALCL. While most ALCL (ALKomas) are characterized by presence NPM‐ALK fusion protein, product t(2;5)(p23;q35), 10–20% ALKomas contain variant ALK fusions, including ATIC‐ALK, TFG‐ALK, CLTC‐ALK (previously designated CLTCL‐ALK), TMP3‐ALK, and MSN‐ALK. TMP3‐ALK TMP4‐ALK fusions also have detected inflammatory myofibroblastic tumors (IMTs), making clear that...
Abstract Real‐time polymerase chain reaction (PCR) is a frequently used technique in molecular diagnostics. To date, practical guidelines for the complete process of optimization and validation commercial in‐house developed diagnostic methods are scare. Therefore, we propose guiding principle real‐time PCR assays. Based on literature, existing guidelines, personal experience, created checklist that can be different steps development Furthermore, determination target values reproducibility...
Abstract Multiple myeloma (MM) is consistently preceded by precursor conditions recognized clinically as monoclonal gammopathy of undetermined significance (MGUS) or smoldering (SMM). We interrogate the whole genome sequence (WGS) profile 18 MGUS and compare them with those from 14 SMMs 80 MMs. show that cases a non-progressing, stable condition ( n = 15) are characterized later initiation in patient’s life absence defining genomic events including: chromothripsis, templated insertions,...
Background: The long-term outcome for patients with aggressive non-Hodgkin's lymphoma (NHL) is poor. Consequently, the European Organization Research and Treatment of Cancer Lymphoma Group designed a prospective randomized trial to investigate whether high-dose chemotherapy plus autologous bone marrow transplantation (ABMT) after standard combination improves survival. Methods: Patients aged 15–65 years NHL received three cycles CHVmP/BV polychemotherapy (i.e., cyclophosphamide, doxorubicin,...
Stratification of patients for targeted and immune-based therapies requires extensive genomic profiling that enables sensitive detection clinically relevant variants interrogation biomarkers, such as tumor mutational burden (TMB) microsatellite instability (MSI). Detection single multiple nucleotide variants, copy number MSI, TMB was evaluated using a commercially available next-generation sequencing panel containing 523 cancer-related genes (1.94 megabases). Analysis formalin-fixed,...
Somatic multigene analysis by next-generation sequencing (NGS) is routinely integrated in medical oncology for clinical decision-making. However, with the fast-growing number of recommended and required genes as well pan-cancer biomarkers, small panels have become vastly insufficient. Comprehensive genomic profiling (CGP) is, thus, to screen clinically relevant markers. In this multicentric study, we report on an extensive across seven centers comparing results novel OncoDEEP CGP assay...
Abstract The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) study assessed the feasibility of using comprehensive genomic profiling (CGP) in clinical decision-making patients with advanced cancers. This multi-center enrolled 872 from 12 hospitals. CGP was performed on tumor tissues a standardized panel (523 genes) across nine laboratories success 93% and median turnaround time 29 days. Actionable markers were identified 81% patients, substantially higher than 21%...
The use of targeted Next Generation Sequencing (NGS) for the diagnostic screening somatic variants in solid tumor samples has proven its high clinical value. Because large number ongoing trials a multitude growing genes, as well detection and emerging pan-cancer biomarkers including microsatellite instability (MSI) mutation burden (TMB), currently employed gene panels will become vastly insufficient near future. Here, we describe validation implementation hybrid capture-based comprehensive...
ObjectivesImmune checkpoint inhibitors (ICIs) improved outcomes in non-small cell lung cancer (NSCLC) patients. We report the predictive utility of human leukocyte antigen class I (HLA-I) diversity and tumor mutational burden (TMB) by comprehensive next-generation sequencing.Methods126 patients were included. TMB high was defined as ≥ 10 nonsynonymous mutations/Mb. Patients exhibit HLA-I if at least one locus upper 15th percentile for DNA alignment scores.ResultsNo difference response rate...
The most recent and powerful prognostic instrument established for myelodysplastic syndromes (MDS) is the International Prognostic Scoring System (IPSS), which primarily based on medullary blast cell count, number of cytopenias, cytogenetics. Although this system has substantial predictive power in MDS, further refinement necessary, especially as far lower-risk patients are concerned. Histologic parameters, have long proved to be associated with outcome, promising candidates improve accuracy...
The inevitable switch from standard molecular methods to next-generation sequencing for the profiling of tumors is challenging most diagnostic laboratories. However, fixed validation criteria accreditation are not in place because great variability and aims. Here, we describe a custom panel hotspots 24 genes detection somatic mutations non-small cell lung carcinoma, colorectal carcinoma malignant melanoma starting FFPE sections, using 14, 36 5 cases, respectively. targeted were selected...